BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
BioMarin Pharmaceutical (BMRN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$110.27 | $140.00 | $72.00 | 22.50% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for BioMarin Pharmaceutical comes to $110.27. The forecasts range from a low of $72.00 to a high of $140.00. The average price target represents an increase of 22.5% from the last closing price of $90.02.
Analyst Price Targets (22)
Broker Rating
BioMarin Pharmaceutical currently has an average brokerage recommendation (ABR) of 1.48 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.64 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 19 are Strong Buy, representing 76% of all recommendations. A month ago, Strong Buy represented 68%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BMRN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 18 | 17 | 17 | 17 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 7 | 8 | 8 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.48 | 1.56 | 1.64 | 1.64 | 1.69 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/20/2024 | Not Identified | Not Identified | Hold | Strong Buy |
8/6/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Scotiabank | George Farmer | Hold | Hold |
8/6/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
8/5/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
8/5/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
7/25/2024 | Canaccord Genuity | Whitney Ijem | Hold | Hold |
6/27/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/31/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
5/17/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Hold |
5/14/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
4/1/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
4/1/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
3/29/2024 | Goldman Sachs | Salveen Richter | Not Available | Strong Buy |
2/23/2024 | Not Identified | Not Identified | Hold | Hold |
11/28/2023 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.48 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 25 |
Average Target Price | $111.13 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | 0.77 |